Answers are grounded in this paper and cite their sources.
In clinical practice settings, patient-reported benefits of dupilumab were maintained in survey respondents during long-term treatment up to 36 months while the use of concomitant AD therapies reduced.
No takes yet. Share an insight, caveat, or question.
Kimball et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: